Fulgent Genetics (FLGT) Current Deferred Revenue (2018 - 2026)

Fulgent Genetics has disclosed Current Deferred Revenue across 9 years of filings, most recently posting $3.0 million for Q1 2026.

• Current Deferred Revenue for Q1 2026 came in at $3.0 million, up 6.74% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.0 million (up 6.74% YoY), and the FY2025 annual result was $3.6 million, up 62.71% from the prior year.
• Current Deferred Revenue came in at $3.0 million for Q1 2026 at Fulgent Genetics, down from $3.6 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $14.1 million in Q1 2022 to a low of $2.2 million in Q4 2024.
• The 5-year median for Current Deferred Revenue is $2.8 million (2024), against an average of $3.9 million.
• Across the five-year window, Current Deferred Revenue plunged 80.62% in 2023 and surged 62.71% in 2025, its largest moves.
• Fulgent Genetics' Current Deferred Revenue stood at $3.2 million in 2022, then dropped by 10.16% to $2.9 million in 2023, then fell by 22.27% to $2.2 million in 2024, then soared by 62.71% to $3.6 million in 2025, then decreased by 17.28% to $3.0 million in 2026.
• The last three Current Deferred Revenue figures came in at $3.0 million (Q1 2026), $3.6 million (Q4 2025), and $2.3 million (Q3 2025), per Business Quant data.